Xeris Biopharma is a technology company.
Xeris Biopharma has raised $40.0M across 2 funding rounds.
Xeris Biopharma has raised $40.0M in total across 2 funding rounds.
Xeris Biopharma has raised $40.0M in total across 2 funding rounds.
Xeris Biopharma's investors include OMX Ventures.
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS) is a commercial-stage biopharmaceutical company headquartered in Chicago, Illinois, focused on developing and commercializing innovative, ready-to-use therapies for chronic endocrine and neurological diseases.[1][2][3] It builds products like Gvoke (ready-to-use glucagon injection for severe hypoglycemia in diabetes patients), Recorlev (levoketoconazole for endogenous Cushing's syndrome), and Keveyis (for periodic paralysis variants), serving patients with unmet needs in emergency glucose elevation, cortisol inhibition, and rare neuromuscular conditions.[1][2] These address critical problems such as reconstitution challenges in injectables, improving rapid administration, patient outcomes, and ease of use; the company reports trailing twelve-month revenue of $266.14 million with growth momentum from higher 2025 revenue guidance amid rising demand for self-administered endocrine therapies.[2]
Founded in 2005, Xeris Pharmaceuticals emerged as a specialty biopharma leveraging novel formulation platforms for ready-to-use, liquid-stable injectables, initially driven by the need for better drug delivery in endocrine therapies.[3][1] Key milestones include the 2017 FDA approval of Gvoke, transitioning it to a commercial-stage company by solving severe hypoglycemia treatment gaps for diabetes patients.[1] In 2020, the acquisition of Strongbridge Biopharma expanded its portfolio into rare diseases like Cushing's syndrome, diversifying revenue and therapeutic focus.[1] This evolution reflects a pivot from early R&D to a growth-oriented firm with ongoing developments like XP-8121 (phase 3 levothyroxine for hypothyroidism).[2]
Xeris stands out in biopharma through its emphasis on ready-to-use injectable and infusible formulations, bypassing reconstitution needs for faster, user-friendly administration.[1][3]
Xeris rides the trend of self-administered therapies for rising chronic illnesses, particularly endocrine disorders amid global increases in diabetes and rare diseases, fueled by healthcare demands for convenient, at-home options.[2][1] Timing aligns with post-pandemic shifts to patient-centric delivery, where market forces like elevated hypoglycemia needs (affecting millions) and regulatory approvals favor its ready-to-use tech over traditional powders.[1][2] It influences the ecosystem by pioneering formulation innovations that reduce administration barriers, potentially setting standards for injectables in biopharma and enabling smaller firms to compete in specialized niches.[1][3]
Xeris is positioned for measured growth, with 2025 revenue guidance upgrades driving expansion despite margin pressures from rising costs and regulation.[2] Upcoming catalysts include XP-8121 phase 3 results, potential rare disease label expansions, and leadership stabilizing operations for pipeline acceleration.[2][3] Trends like chronic illness prevalence and self-injection adoption will shape its path, evolving its influence from niche innovator to broader endocrine leader—building on Gvoke's breakthrough to sustain patient impact in a high-need market.[1][2]
Xeris Biopharma has raised $40.0M across 2 funding rounds. Most recently, it raised $10.0M Series C in March 2018.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Mar 1, 2018 | $10.0M Series C | OMX Ventures | |
| May 1, 2017 | $30.0M Series C | OMX Ventures |